“Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of cannabis that interacts with the serotonin (5-HT)_1A receptor, may possess analgesic and anxiolytic effects. Overall, repeated treatment with low-dose CBD induces analgesia predominantly through TRPV₁ activation, reduces anxiety through 5-HT_1A receptor activation, and rescues impaired 5-HT neurotransmission under neuropathic pain conditions.” https://www.ncbi.nlm.nih.gov/pubmed/30157131 https://insights.ovid.com/crossref?an=00006396-900000000-98870